The World in BriefThis e-newsletter is provided courtesy of Reed CNY Business Law, P.C.
Immigration: U.S. to Suspend the Entry of H1B, L-1 and certain J-1 Visa Holders
U.S. President Donald Trump on April 22, 2020 announced, "Proclamation Suspending Entry of Aliens Who Present a Risk to the U.S. Labor Market Following the Coronavirus Outbreak" ("the Proclamation"). The targets are primarily non-immigrant visa holders or candidates.
The Proclamation suspends the entry of new H-1B, H-2B, L-1, and certain J-1 nonimmigrants, as well as their accompanying spouses and dependents (i.e. H-4, L-2, and J-2 nonimmigrants), with minimal exceptions. The nonimmigrant suspension takes effect at 12:01am EDT on June 24, 2020. The Proclamation will remain in place through December 31, 2020, and may be extended as deemed necessary by the Administration.
Pursuant to Sec.3 (b) of the Proclamation, there are some exceptions for J-1 visa holders seekingtoenterthe United States to provide temporary labor or services essential to the United States food supply chain; and aliens whose entry would be in the U.S. national interest. Also, White House official said college and university professors on J visas and medical worker exemptions were narrowed to allow only those coming in to work on COVID-19 care or research.” Reed Business Law provides the most updated and correct consulting for clients and their employees who would like to come toU.S.
지난 4 월 22 일, 트럼프 미국대통령은 “코로나바이러스로 인한 미국노동시장 보호를 위한 외국인 입국제한조치”를 선포했습니다.본대통령령은비이민비자신청대상자에게해당되는조치입니다.내용은H1B(취업비자),L-1(주재원비자), 및 J-1 (인턴/연수비자) 등의 비자소지자와 그 가족들에게 해당되는 것으로 지난 6 월 24 일 부터 시행되었습니다. 해당비자를발급받은외국인들은올해12월31일까지미국에입국을할수없습니다.
Blockchain Technology: U.S. seeks to 'onshore' drug production in response to COVID-19.
Data sharing throughout the pharma supply chain is critical for maintaining product integrity and quality. Considering the number of handoffs that occur throughout the entire process, and the multitude of parties involved from manufacturers to the end consumers, tracibility is one of the few ways to be able to remove marketed products that are later found to be dangerous. The Drug Supply Chain Security Act (DSCSA) mandates product serialization, reaching full implementation in 2023. One of its key requirements is a “standardized numeric identifier” applied to each salable package, with this information maintained for at least for six years.
Blockchainisapotentialsolutionforthesevulnerabilities.Thefeaturesthatmakeitattractivearetheability to share data with multiple stakeholders and the protection of data across the entire network. With these advantages in mind, in 2017 the MediLedger project began, representing a collaboration of pharma supply stakeholders — Pfizer, Lilly, McKesson, Amerisource Bergen, Walgreens, and Walmart. The goal was to go beyond simple compliance with the DSCSA, and to make blockchain a practical solution for all participants in the supply chain. MediLedger needed to address implementation problems, describe how it would be constructed from an IT perspective, list its advantages over other potential solutions, fashion an onboarding mechanism for the various participants, create a governing structure, identify how the system wouldbecompatiblewithothersystems,anddevelopavalueproposition.ReedBusinessLawhasconducted blockchain technology seminars and would be glad to present the possible benefit to members of the bio- pharma supply chain. Please contact Donghoo Sohn to discuss our expertise and yourneeds.
바이오제약산업에서 제약의 유통에 관한 정보공유는 품질공정에 직접적인 영향을 끼치므로 매우 중요하다고 할수있습니다. 제약의유통과정중에발생하는손실, 그리고본과정에참여하는많은당사자들을고려해보면추적가능한 유통관리는향후일어날수있는리스크를최대한줄일수있는유용한방법입니다.“제약유통관리에관한법”(DSCSA)는 모든약품의시리얼화를2023년까지완료할수있도록제안하고있습니다.
블록체인 기술은 본 법안의 현실화를 촉진시킬수 있는 효율적인 방법이 될수있습니다. 네트워크내의 모든 참여자들이 데이터를 공유함으로써 본 정보를 보호할수있다는 점은 분명 매력적입니다. 이러한 이해를 바탕으로 지난 2017 년 MediLedger project 가 시작되어 제약 유통산업을 보호하고자 파이자제약, 릴리제약, 맥커슨, 월그린, 월마트등 여러 기업들이본프로젝트에참여했습니다. 프로젝트의궁극적인목표는DSCSA의제도를단순히이행하는것에그치지않고 나아가 블록체인기술이 해당 유통산업의 주체들에게 실질적인 해결책을 제시할수있도록 하는것입니다. 저희로펌은 블록체인기술에 관한 세미나를 시라큐스로스쿨에서 여러차례 진행하고 바이오제약산업과의 협업에 대해 누차강조해왔습니다.